Nivolumab in Relapsed Pediatric Solid Tumors

Hadassah Medical Center

Status and phase

Unknown

Phase 2

Phase 1

Conditions

Antibodies, Neoplasm

Treatments

Drug: Nivolumab,low dose cyclophosphamide

Study type

Interventional

Funder types

Other

Identifiers

NCT02901145

0506-15-HMO

Details and patient eligibility

About

patients with progressive/relapsed solid tumors who failed first line therapy , will be treated biweekly with the anti PD1- Nivolumab. at least one month after treatment initiation low dose cyclophosphamide will be started .

patients on trial will submit tissue and blood tests for whole exome an immune genomic signature. patients will also undergo repeated immunophenotype as part of follow up.

Full description

Programmed cell death 1 (PD-1) is an inhibitory receptor that prevents immune activation. PD-1 blockade can mediate reactivation of immune mediated tumor killing leading to tumor regression . Another mechanism of tumor associated immune inactivation is elevation of rates of T regulatory cells. This process may be prevented by treatment with low dose cyclophosphamide.

Objective:

This study will evaluate safety and tolerability of the anti PD1 antibody Nivolumab combined with other immunomodulating treatments, in pediatric patients with relapsed/progressive solid tumors

Method:

Patients will be treated with IV Nivolumab 3mg/kg over 60 minutes on day 1 and 15 of each cycle of 28 days.

Dose finding phase:
1. Six patients will be accrued for the first cohort and treated for 1 month
2. If an adverse event >grade 2 will occur in>2 patients, study medication dose will be reduced by 25% and another cohort of 6 patients will be accrued on the reduced dose.
3. Dose finding cohorts will be accrued until determination of a dose with allowed DLT
Expansion phase
1. Following dose determination patients will be accrued, to the final number of 30 patients
2. Cyclophosphamide at the dose of 50 mg/dayx7days every 14 days (one week on one week off ) will be started . immunophenotype will be done every 28 days and dose of cyclophosphamide will be elevated by 25mg /day every month until highest ratio of CD8/CD25FOXP3 cells will be reached for every child
3. All patients will be treated for 1 year or until imaging proven disease progression.
Required follow up
1. All patients will undergo tumor bed imaging (CT/MRI-based on tumor location) with metastatic evaluation (according to standar follow up) every 4 months
2. Tumor response will be measured based on RECIST criteria
3. Toxicity assessment will be done according to the CTCAE v. 4.03

c. Collateral studies:

Immunohistochemical analysis for PD1 and PDL1 will be done on pretreatment paraffin embedded tissue to estimate it's ability to predict response.
Immune profile of peripheral blood lymphocytes including CD3+, CD4+, CD8+ FOX P3+ cells and it's correlation to objective response to therapy.
Exome sequencing of the tumor and peripheral blood will be done for every patient.

Exome will be evaluated for driver mutations and immunologic genomic signature.

Enrollment

30 estimated patients

Sex

All

Ages

1 to 21 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ages Eligible for Study: 12 Months and older
Patients must have had histologic verification of malignancy at original diagnosis or relapse

Eligible pathologies:
1. neuroblastoma following lack of complete response to at least two lines of therapy
2. rhabdomyosarcoma following progression after first line therapy
3. Ewing sarcoma following progression after second line of therpy
4. Osteosarcoma following progression after first line of therapy all other pathologies will be discussed with PI
Patients must have measurable disease
Patient's current disease state must be one for which there is no known curative therapy
Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer treatment
1. At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
2. At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines
3. at least 56 days must have elapsed after transplant or stem cell infusion; patients with prior allogeneic transplants are not eligible
Blood counts recovery including ANC >= 750/mm^3 and Platelet count >= 50,000/mm^3
Creatinine clearance ≤ 1.5 ULN
liver function:Total bilirubin ≤ 2 ULN, ALT or AST ≤ 2.5 ULN (or < 5 in case of liver impairment)
Life expectancy of at least 4 months
Pregnancy:
1. Negative pregnancy test in women of childbearing potential
2. Use of an effective contraceptive method during the whole treatment and
3. up to 3 months after the completion of treatment in males and females
prior informed consent signed

Exclusion criteria

Patients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within 7 days of enrollment on study
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients with a history of any grade autoimmune disorder are not eligible; asymptomatic laboratory abnormalities (e.g. antinuclear antibody [ANA], rheumatoid factor, altered thyroid function studies) will not render a patient ineligible in the absence of a diagnosis of an autoimmune disorder
Patients with >= grade 2 hypothyroidism due to history of autoimmunity are not eligible; note: hypothyroidism due to previous irradiation on thyroidectomy will not impact eligibility
Patients who have an uncontrolled infection are not eligible.
Patients with active autoimmune disease. (any autoimmune state requiring medical treatment-including chronic medications)all immune modifying drugs should be stopped at least 7 days prior to enrollment.